SEC Form 4 · accession 0001209191-18-044412

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 26, 2018

Accepted (ET)

Jul 30, 2018 · 4:43 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604464

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Jul 26, 2018	S	3,800	$39.02	D	93,878	I	See footnote
Common Stock^F3	Jul 26, 2018	S	100	$39.45	D	93,778	I	See footnote
Common Stock^F4,F3	Jul 27, 2018	S	2,200	$36.55	D	91,578	I	See footnote
Common Stock^F5,F3	Jul 27, 2018	S	1,700	$37.53	D	89,878	I	See footnote
Common Stock	holding	—	—		—	812,613	D

No Table II lines on this filing.

F1Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.40 to $39.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $36.825. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.20 to $37.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.